# Zelluna

Source: https://onco.cc/companies/zelluna/  
OnCo record `zelluna` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Zelluna is a Norwegian company that gives natural killer cells, a type of immune cell, a T-cell receptor so they can recognise a marker found inside many solid tumours. Its first product, ZI-MA4-1, is in an early trial.

## Summary

Zelluna Immunotherapy AS was established in 2016 and is headquartered at the Oslo Cancer Cluster Innovation Park in Oslo, according to the company; in March 2025 it combined its business with Ultimovacs ASA to form Zelluna, a public company listed on Euronext Oslo Bors under the ticker ZLNA. It develops TCR-NK cell therapies, natural killer cells engineered to express a T-cell receptor, for solid cancers. The lead programme ZI-MA4-1 targets MAGE-A4 presented on HLA-A*02:01. Its first registered cancer trial, NCT07613723 (ZIMA-101), a phase 1 dose-escalation study of ZI-MA4-1 after cyclophosphamide and fludarabine in HLA-A*02:01-positive patients with MAGE-A4-expressing solid tumours, including ovarian cancer, squamous non-small cell lung cancer, synovial sarcoma and head and neck cancer, at sites in London and Manchester, was posted on ClinicalTrials.gov in May 2026.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Zelluna ASA; Zelluna Immunotherapy AS
- HQ: Oslo
- Type: cell-therapy
- Website: https://zelluna.com/
- Ticker: ZLNA

## Notes

- Founding year, headquarters, listing and the Ultimovacs combination are from the company's About page, read on 29 October 2026. Ultimovacs has no record in the corpus. Financial results were not read, so no funding rows are recorded.

## Sources

- Official website: https://zelluna.com/
- About Zelluna: https://zelluna.com/about-zelluna
- Share information: https://zelluna.com/investors/share-information
- ClinicalTrials.gov: ZIMA-101 phase 1 trial of ZI-MA4-1 (NCT07613723): https://clinicaltrials.gov/study/NCT07613723

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Squamous cell carcinoma of the lung](https://onco.cc/cancers/lung-squamous-cell-carcinoma/), [Synovial sarcoma](https://onco.cc/cancers/synovial-sarcoma/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/), [NK cell therapy and CAR-NK](https://onco.cc/technologies/nk-cell-therapy/), [TCR-T cell therapy](https://onco.cc/technologies/tcr-t/)
- targets: [MAGE-A4](https://onco.cc/targets/mage-a4/)

---
JSON: https://onco.cc/api/v1/entities/zelluna.json